Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients

Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable

(2016) Erkki Soini et al.   CLINICAL THERAPEUTICS

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland

(2015) Erkki J. Soini et al.   ADVANCES IN THERAPY

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

(2014) P. Dorian et al.   EUROPEAN HEART JOURNAL

Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data

(2014) Taru Hallinen et al.   BMJ Open

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation

(2013) Anuraag R. Kansal et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

International Normalized Ratio (INR) Monitoring and Percent Time in Therapeutic INR Range (TTR) Have Impact on Patient’s Quality of Life? Application of Beta Regressions in a Prospective 3 Months Setting

(2013) E.J. Soini et al.   VALUE IN HEALTH

Quality of the Finnish Hospital Discharge Register: A systematic review

(2012) Reijo Sund   SCANDINAVIAN JOURNAL OF PUBLIC HEALTH

Catalogue of EQ-5D Scores for the United Kingdom

(2011) Patrick W. Sullivan et al.   MEDICAL DECISION MAKING

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct Costs of Patients With Stroke Can Be Continuously Monitored on a National Level

(2011) Atte Meretoja et al.   STROKE

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up

(2010) E. J. O. Soini et al.   ANNALS OF ONCOLOGY

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Prognostic Value of the Modified Rankin Scale Score for Long-Term Survival after First-Ever Stroke

(2008) Krista F. Huybrechts et al.   CEREBROVASCULAR DISEASES

Optimal Cost-Effectiveness Decisions: The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI)

(2008) Garry R. Barton et al.   VALUE IN HEALTH